

Adaora Adimora MD, MPH, FIDSA

Stephen B. Calderwood MD, FIDSA

HIV Medicine Association

(via Andrea Weddle at aweddle@hivma.org)

September 8, 2015

Dear Dr. Adimora and Dr. Calderwood

Very many thanks for your letter, which has been passed to me by Kevin Bernier and Tom Evegan.

We completely agree about the severity and risks of toxoplasmosis and the absolute need to provide effective treatment for this neglected disease. To this end, Turing Pharmaceuticals is committed to investing in the development of improved formulations as well as next generation toxoplasmosis treatments. We are also determined to ensure that all patients can access our medicine.

We fully understand your concerns about the cost to hospital pharmacies. The pharmaceutical pricing model is extraordinarily complex, but I believe your estimate of treatment costs cannot be generalized.

Regarding your concerns about distribution, my commercial colleagues assure us that institutions may order DARAPRIM® through Turing's exclusive distribution partner, Integrated Commercialization Solutions (ICS). Orders can be emailed to daraprimdirect@icsconnect.com or by calling 800-554-6919.

With this note is a document that describes our company's principles and our comprehensive programs to ensure access and affordability. I sincerely hope this provides the reassurance you seek.

We have considerable regard for IDSA and HIVMA as organizations committed to improving human health and advancing medical science. We look forward to working with you on these shared objectives.

Sincerely,

A handwritten signature in black ink, appearing to read 'Eliseo Salinas', with a horizontal line drawn underneath the signature.

Eliseo Salinas MD, MSc

President Research & Development